Gaucher Disease, Type 1

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

A Gaucher Disease Gene Therapy Trial With FLT201

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

A Gene Therapy Study in Patients With Gaucher Disease Type 1

Baby Detect : Genomic Newborn Screening

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease

A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy.

Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy

Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs

Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)

An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease